Form4insider filings, from the source

SEC Form 4 · accession 0000899243-15-002778

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Patrick G Enright
Director · 10% Owner
Period of report
Aug 11, 2015
Accepted (ET)
Aug 11, 2015 · 11:29 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueF1,F2Aug 11, 2015C3,873,530—A3,873,530IBy: Longitude Venture Partners II, L.P.
Common Stock, $0.0001 par valueF1,F2Aug 11, 2015C3,248,600—A7,122,130IBy: Longitude Venture Partners II, L.P.
Common Stock, $0.0001 par valueF2Aug 11, 2015P312,500$16.00A7,434,630IBy: Longitude Venture Partners II, L.P.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A Convertible Preferred StockF1,F2,F4—Aug 11, 2015C3,873,530D——Common Stock3,873,5300I
Series B Convertible Preferred StockF1,F2,F4—Aug 11, 2015C3,248,600D——Common Stock3,248,6000I

Explanation of responses